Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

This publication has 44 references indexed in Scilit:

• Chronic hepatitis B
  Hepatology, 2007
• Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
  Hepatology, 2006
• Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis
  Annals of Internal Medicine, 2005
• Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1
  Gastroenterology, 2004
• Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study
  Journal of Hepatology, 2003
• Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population
  Published by American Medical Association (AMA) ,2003
• Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data
  Journal of Gastroenterology and Hepatology, 2002
• Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus
  Annals of Internal Medicine, 2001
• Long–Term Beneficial Effect of Interferon Therapy in Patients With Chronic Hepatitis B Virus Infection
  Hepatology, 1999
• A One-Year Trial of Lamivudine for Chronic Hepatitis B
  New England Journal of Medicine, 1998